Advantages and Unique Features of Tirzepatide
More Potent Weight Loss Effects
As mentioned earlier, Tirzepatide demonstrated stronger weight loss effects than semaglutide in clinical trials. For severely obese patients with a BMI of 35 or higher, Tirzepatide may be the preferred option.
Equally Impressive Glycemic Control
For obese patients with type 2 diabetes, tirzepatide’s glycemic control is even more pronounced than its weight-loss effects. The SURPASS series of studies showed that tirzepatide 15 mg reduced HbA1c by 2.0–2.3%, a result that ranks among the top levels among currently available antidiabetic medications.
Once-weekly injection ensures high adherence
Compared to medications requiring daily injections or oral administration, the once-weekly dosing schedule significantly improves patient adherence. Clinical data show that among GLP-1 agonists, adherence rates are significantly higher for patients on once-weekly regimens than for those on daily regimens.
Potential Cardiovascular Benefits
Although the cardiovascular outcomes trial for tirzepatide (SURPASS-CVOT) has not yet been completed, the industry remains optimistic about its cardiovascular benefits based on the overall cardiovascular protective effects of GLP-1 agonists and tirzepatide’s positive data regarding blood pressure reduction and lipid profile improvement.
Side Effects and Precautions: What You Need to Know
Common Side Effects (Incidence >5%)
According to the prescribing information and clinical data, common side effects of tirzepatide include:
Gastrointestinal reactions (most common): – Nausea (approximately 30–40%) – Diarrhea (approximately 20–25%) – Vomiting (approximately 10–15%) – Constipation (approx. 10–15%) – Abdominal pain (approx. 10%) – Dyspepsia (approx. 8%)
Other Side Effects: – Decreased appetite (common, but an expected effect) – Fatigue (approx. 5–8%) – Injection site reactions (redness, swelling, itching) – Hypoglycemia (increased risk when used in combination with other antidiabetic medications)
Serious Side Effects (Rare but Requiring Vigilance)
Risk of Medullary Thyroid Carcinoma (MTC): – Animal studies indicate that tirzepatide may increase the incidence of thyroid C-cell tumors – Human data are not yet conclusive, but the product label includes a black box warning – Contraindications: Patients with a history of MTC or a family history of MTC, and patients with multiple endocrine neoplasia type 2 (MEN2)
Pancreatitis: – Pancreatitis has been reported with all GLP-1 agonists – Seek immediate medical attention if persistent severe abdominal pain or vomiting occurs
Acute Kidney Injury: – May be caused by dehydration resulting from severe vomiting or diarrhea – Patients with renal impairment require close monitoring
Gallbladder disease: – Rapid weight loss may increase the risk of gallstones – Seek medical evaluation if right upper quadrant pain or jaundice occurs
Precautions for Special Populations
Pregnancy: Contraindicated. Animal studies have shown adverse effects on the fetus.
Breastfeeding: Not recommended. The drug may be excreted in breast milk.
Women planning pregnancy: It is recommended to discontinue the drug for at least 2 months before attempting to conceive.
Under 18 years of age: Safety and efficacy have not been established.
Elderly patients (65 years and older): May be used, but treatment should begin at a low dose with close monitoring.
Patients with hepatic or renal impairment: – Mild to moderate: No dose adjustment required – Severe: Data are limited; use with caution is recommended
Weight Rebound After Discontinuation: A Reality You Must Face
How Severe Is the Rebound?
This is perhaps the most controversial aspect of tirzepatide (and all GLP-1 agonists): weight rebound is almost inevitable after discontinuation.
According to Eli Lilly’s SURMOUNT-4 study: – Patients who discontinued tirzepatide after 12 months of use – Regained an average of 60–70% of their weight loss within one year of discontinuation – Improvements in blood pressure, blood lipids, and blood glucose levels also reversed
Why Does Weight Rebound?
This is related to the drug’s mechanism of action:
Tirzepatide artificially suppresses appetite and food intake by exogenously supplementing high doses of GLP-1 and GIP. However, long-term use of exogenous agonists may suppress the body’s own GLP-1 secretion (negative feedback regulation).
Once the medication is discontinued, exogenous hormone levels drop sharply, while endogenous secretion has not yet recovered, leading to: – A rebound in hunger – A significant increase in appetite – Rapid weight regain
How can weight regain be avoided or delayed?
Strategy 1: Stepwise dose reduction and discontinuation – Do not stop abruptly at 15 mg – Gradually reduce the dose to 12.5 mg → 10 mg → 7.5 mg → 5 mg → 2.5 mg – Maintain each dose for 4–8 weeks
Strategy 2: Combine with lifestyle changes – Establish healthy eating habits during treatment – Develop an exercise routine – The reduced stomach capacity achieved during treatment may help maintain weight
Strategy 3: Long-Term Maintenance Dose – Some patients may need to take the lowest effective dose (e.g., 2.5 mg or 5 mg) long-term to maintain weight
Strategy 4: Managing Psychological Expectations – Clearly understand: Medication is only a tool, not a permanent solution – The purpose of weight loss during treatment is to build confidence, improve metabolic markers, and buy time for long-term lifestyle changes
Real Patient Case Study: From Hesitation to Transformation
The following is a real client’s medication record (shared with permission; personal information has been anonymized):
Patient Profile
Gender: Female
Age: 35
Occupation: Product Manager at an internet company
Starting Weight: 82 kg (Height: 162 cm, BMI: 31.2)
Medical History: Mild fatty liver, elevated blood lipids; had tried various weight-loss methods without success
Treatment Progress
Week 0 (Before Deciding to Start Treatment): She told me she had tried dieting, the ketogenic diet, personal training at the gym, and even meal replacement shakes, but either couldn’t stick with them or lost weight only to regain it. She said, “I’m like a balloon—I lose weight, then I just inflate again.”
I advised her to first undergo a comprehensive physical examination at the hospital to confirm there were no contraindications before considering Tirzepatide.
Weeks 1–4 (2.5 mg dose): During the first week of treatment, Xiaolin experienced significant side effects: nausea, loss of appetite, and the urge to vomit at the smell of greasy food. She even considered giving up.
I told her this was a normal adjustment period and advised her to: – Eat small, frequent meals, taking just a little at a time – Avoid greasy foods – Stay well-hydrated
By week 4, she weighed herself: 78.5 kg, a loss of 3.5 kg.
Weeks 5–12 (5 mg dose): After the adjustment period, Xiaolin’s side effects significantly subsided. She said, “I don’t crave delicious food anymore; just a few bites make me feel full.”
During this phase, her weight steadily decreased, reaching 74 kg by week 8 and 71 kg by week 12.
By week 12, she had lost a total of 11 kg (13.4%), and a follow-up examination showed that her fatty liver condition had improved.
Weeks 13–20 (7.5 mg dose): She entered a plateau phase, and the rate of weight loss slowed. By week 20, her weight was 68.5 kg, with a cumulative weight loss of 13.5 kg (16.5%).
Week 21 to present (10 mg dose, currently in week 28): Her weight is currently maintained in the 66–67 kg range, with a cumulative weight loss of approximately 15 kg.
Kobayashi said, “My appetite is now about half of what it used to be, but I actually feel more energetic than before. I used to feel tired all the time, but now I can get up early every day to exercise.”
Side Effect Log
Nausea: Pronounced during the first 4 weeks, then gradually subsided
Constipation: Occasional, alleviated by increasing dietary fiber and fluid intake
Injection site: Mild redness and swelling, resolved on its own within 1–2 days
Her Advice
“If you’re like me and have tried many methods without success, you might want to consider Tirzepatide. But be prepared for the following: 1. The first two weeks are really tough, but you’ll get through it; 2. This isn’t magic—you still need to stick to a healthy diet; 3. You might regain weight after stopping the medication, so I’m already thinking about how to taper off gradually.”
Who Should Use It and Who Should Avoid It?
Who Should Use It
Based on guidelines and clinical experience, tirzepatide is suitable for the following groups:
Medical Indications (FDA-approved): – Obese patients with a BMI ≥30 – Overweight patients with a BMI ≥27 and at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia, sleep apnea, etc.)
Common User Groups in Clinical Practice: – Individuals with a history of repeated weight loss failures – Patients with metabolic syndrome – Patients whose quality of life is impaired by obesity (e.g., joint pain, shortness of breath)
Absolute Contraindications
Tirzepatide is strictly contraindicated in the following groups: – Individuals with a personal or family history of medullary thyroid carcinoma (MTC) – Patients with type 2 multiple endocrine neoplasia syndrome (MEN2) – Patients with known hypersensitivity to tirzepatide or other GLP-1 agonists – Pregnant or breastfeeding women – Children and adolescents under 18 years of age
Relative contraindications/cautionary groups
The following groups should use Tirzepatide with caution following a physician’s evaluation: – Individuals with a history of pancreatitis – Patients with severe gastrointestinal disorders (e.g., gastroparesis, inflammatory bowel disease) – Patients with severe renal impairment – Patients with severe hepatic impairment – Patients with suicidal tendencies or severe psychiatric disorders – Diabetic patients currently using insulin or sulfonylurea medications (risk of hypoglycemia)
Medication Recommendations and Summary
Preparation Before Starting Medication
Recommended Medical Tests: – Complete blood count (CBC), urinalysis – Liver and kidney function tests – Thyroid function (calcitonin levels) – Fasting blood glucose, HbA1c – Comprehensive lipid profile – Abdominal ultrasound (liver, gallbladder, pancreas, spleen) – Electrocardiogram (ECG)
Mental Preparation: – Clearly define treatment goals (How much weight to lose? Which health indicators to improve?) – Understand potential side effects – Be prepared for long-term medication or management
Precautions During Medication
Dietary Recommendations: – Eat smaller, more frequent meals; avoid overeating – Reduce intake of high-fat and high-sugar foods – Increase intake of protein and dietary fiber – Stay well-hydrated (1,500–2,000 ml daily)
Exercise Recommendations: – You may moderately increase your exercise volume while on medication – Recommended: Moderate-intensity activities such as brisk walking, swimming, and yoga – Avoid: Vigorous exercise on an empty stomach (risk of hypoglycemia)
Monitoring Parameters: – Record weight and waist circumference weekly – Re-check blood glucose, blood lipids, and liver and kidney function every 1–3 months – Seek medical attention promptly if you experience any discomfort
In Closing
Tirzepatide is indeed a revolutionary weight-loss medication that has given hope to many people who have struggled with obesity. However, it is not a panacea, nor is it without its drawbacks.
We should not blindly embrace a drug simply because it is effective, nor should we dismiss it entirely because of its side effects. What matters is: – Making informed decisions – Using the medication under the guidance of a qualified healthcare professional – Developing a long-term commitment to health management
If you are considering using tirzepatide, we recommend asking yourself the following questions: 1. Does my BMI meet the criteria for use? 2. Do I have any contraindications? 3. Can I tolerate the potential side effects? 4. Am I willing to accept the risk of weight regain after discontinuing the medication? 5. Am I willing to make lifestyle changes while taking the medication?
If the answer to all of the above questions is yes, then tirzepatide may be an option worth considering.